Due to a limited supply, we are unable to accept phone calls to schedule COVID-19 vaccinations.
For the most up-to-date information, please check our COVID-19 Vaccination Website.

 

Additional Coronavirus Updates >

MENU

Fox Chase Cancer Center News

November 1, 2010

High-dose, Short-course Radiation for Prostate Cancer Does Not Increase Side Effects or Reduce Quality of Life

SAN DIEGO, CA (November 1, 2010) – When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient’s overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.

November 1, 2010

Fox Chase Researchers Identify Risk Factors for the Spread of Breast Cancer to Lymph Nodes

SAN DIEGO, CA (November 1, 2010) – Breast cancer, one of the most prevalent cancers in women, afflicts an additional 200,000 women each year and causes about 40,000 deaths annually.

October 27, 2010

Fox Chase Holds Free Event For Lung Cancer Patients

PHILADELPHIA (October 27, 2010) – Fox Chase Cancer Center invites lung cancer patients and their caregivers to the free event, “Together Facing Lung Cancer”, on Tuesday, November 16 at 5:00 p.m.

The event will be held on the Fox Chase Cancer Center campus (333 Cottman Avenue, Philadelphia).

October 25, 2010

Fox Chase to Hold Jane Pepper Women's Cancer Symposium

PHILADELPHIA (October 25, 2010) – Fox Chase Cancer Center will host the Jane Pepper Women’s Cancer Symposium on November 6, 2010, from 2:30 p.m. to 5:30 p.m. on their main Campus (333 Cottman Avenue, Philadelphia). The symposium will convene oncologists, cancer survivors and their families, authors, and interested members of the community to discuss issues surrounding women’s cancers and to celebrate survivorship. The series was named in honor of Jane Pepper, past President of the Pennsylvania Horticultural Society, and her late husband G.

Andrew Andrews, PhD
October 21, 2010

Andy Andrews, PhD, Joins Fox Chase's Cancer Biology Research Program

PHILADELPHIA (October 21, 2010) – Andy Andrews, PhD, has joined Fox Chase Cancer Center as an assistant professor in the Cancer Biology Program. Andrews comes to Fox Chase after concluding a postdoctoral fellowship at the University of Colorado in the lab of HHMI Investigator Dr. Karolin Luger, PhD. His area of focus is the field of epigenetics, which deals with changes in gene expression controlled by mechanisms outside of the underlying DNA sequence.

October 19, 2010

Fox Chase Cancer Center Researchers Advocate for More Education and Attention Regarding Rare Breast Cancer

PHILADELPHIA (October 19, 2010) – Inflammatory breast cancer (IBC), an aggressive and rare malignancy, is often initially misdiagnosed as an infection or rash. However, getting the correct diagnosis quickly is critical for patients because the disease spreads beyond the breast in a matter of just days or weeks.

October 15, 2010

Prashant C. Shah, MD, Joins Fox Chase's Department of Surgical Oncology

PHILADELPHIA (October 15, 2010) – Prashant C. Shah, MD, has joined Fox Chase Cancer Center’s Department of Surgical Oncology as an attending surgeon in the Division of Thoracic Oncology. He specializes in complex thoracic cancer cases, minimally invasive foregut/esophageal surgery, VATS lung and mediastinal surgery, and the surgical management of mesothelioma. He also has specialized training in treating patients with many types of benign thoracic surgical problems, such as GERD, hyperhidrosis, Barrett’s esophagus, and achalasia.

October 12, 2010

Fox Chase Researchers Uncover Achilles' Heel in Aggressive Breast Tumors

PHILADELPHIA (October 12, 2010) – In an unexpected twist, Fox Chase Cancer Center researchers find that the loss of a single protein, Nedd9, initially slows cancer formation but then makes the tumors that do arise more aggressive. The good news, though, is that the lack of Nedd9 also makes the aggressive tumors more sensitive to a class of drugs that are already used in the clinic.

Pages

Connect with Fox Chase